glutathione calming APLB Glutathione Niacinamide Sunscreen

Treatment options may be available

HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration HG202 is the first CRISPR/Cas13Y RNA-targeting therapy to enter clinical development and the only clinical-stage CRISPR RNA-editing therapy for age-related macular degeneration Preclinical studies in laser-induced CNV mice showed HG202 reduced CNV area by 87%, outperforming both anti-VEGF antibodies and AAV-anti-VEGF gene therapy SHANGHAI and CLINTON (NJ), November 4, 2024 HuidaGene Therapeutics (HuidaGene), a global clinical-stage biotechnology company developing genome medicines, today announced that the US FDA has cleared its HG202 investigational new drug (IND) application for neovascular age-related macular degeneration (nAMD)

Once activated, melanocytes convert the amino acid tyrosine into melanin through a series of enzymatic reactions, primarily involving the enzyme tyrosinase

Acetylation impacts Fli-1-driven regulation of granulocyte colony stimulating factor

Acta 182 (1), 5159 (2015)

K.BlahetaR